Drug intelligence / Profile preview

GO-ECM1

Development stage: Preclinical
Lead developer: GO Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GO-ECM1 is an investigational monoclonal antibody developed by GO Therapeutics that targets tumor-associated truncated O-glycans, specifically the Tn (GalNAc-Ser/Thr) and STn (Sialyl-Tn) antigens. These glycans are considered "super-clean" tumor antigens because they arise from aberrant O-glycosylation pathways unique to cancer cells and are absent in healthy tissues. While other candidates in the GO Therapeutics pipeline target malignant cells directly, GO-ECM1 is specifically designed for solid tumor stroma targeting. By binding to these antigens within the tumor microenvironment, the antibody aims to disrupt the supportive stromal architecture or deliver therapeutic effects to the extracellular matrix of solid tumors.

Targets

STn-MUC1 (Sialyl-Tn-MUC1)Tn (Tn antigen)

Beyond the preview

Go deeper on GO-ECM1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO-ECM1.

Explore the full profile